Date: 8/10/2006 7:30:00 AM

    SAN DIEGO, Aug. 10 /PRNewswire-FirstCall/ -- Vical Incorporated
(Nasdaq: VICL) today announced that it has completed a $9.8 million registered
direct offering of its common stock to a single institutional investor, in
which Vical sold approximately 2.1 million shares pursuant to effective shelf
registration statements at a price of $4.77 per share, the Nasdaq official
closing price on August 8, 2006, with no discounts or commissions.  Proceeds
from the transaction will be used in the further development of Vical's
ongoing programs, as well as for other general corporate purposes.

    This press release shall not constitute an offer to sell or the
solicitation of an offer to buy nor shall there be any sale of these
securities in any state or jurisdiction in which such offer, solicitation or
sale would be unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction.  The shares of common stock
may only be offered by means of a prospectus. Copies of the final prospectus
supplement and accompanying base prospectus can be obtained from the Corporate
Secretary, Vical Incorporated, 10390 Pacific Center Court, San Diego, CA
92121-4340.

    About Vical

    Vical researches and develops biopharmaceutical products based on its
patented DNA delivery technologies for the prevention and treatment of serious
or life-threatening diseases.  Potential applications of the company's DNA
delivery technology include DNA vaccines for infectious diseases or cancer, in
which the expressed protein is an immunogen; cancer immunotherapeutics, in
which the expressed protein is an immune system stimulant; and cardiovascular
therapies, in which the expressed protein is an angiogenic growth factor.  The
company has developed certain infectious disease vaccines and cancer
therapeutics internally.  In addition, the company collaborates with major
pharmaceutical companies and biotechnology companies that give it access to
complementary technologies or greater resources.  These strategic partnerships
provide the company with mutually beneficial opportunities to expand its
product pipeline and serve significant unmet medical needs.  Additional
information on Vical is available at www.vical.com.

    This press release contains forward-looking statements subject to risks
and uncertainties that could cause actual results to differ materially from
those projected, including:  whether any product candidates will be shown to
be safe and efficacious in clinical trials; the timing of clinical trials;
whether Vical or its collaborative partners will seek or gain approval to
market any product candidates; the dependence of the company on its
collaborative partners; and additional risks set forth in the company's
filings with the Securities and Exchange Commission.  These forward-looking
statements represent the company's judgment as of the date of this release.
The company disclaims, however, any intent or obligation to update these
forward-looking statements.



    Contacts:  Investors:                       Media:
               Alan R. Engbring                 Susan Neath
               Vical Incorporated               Porter Novelli Life Sciences
               (858) 646-1127                   (858) 527-3486
               Website:  www.vical.com


SOURCE  Vical Incorporated
    -0-                             08/10/2006
    /CONTACT:  Investors, Alan R. Engbring of Vical Incorporated,
+1-858-646-1127; or Media, Susan Neath of Porter Novelli Life Sciences,
+1-858-527-3486, for Vical Incorporated/
    /Web site:  http://www.vical.com /
    (VICL)

CO:  Vical Incorporated
ST:  California
IN:  HEA MTC BIO
SU:  OFR

BF-CM
-- LATH028 --
7026 08/10/2006 07:30 EDT http://www.prnewswire.com